Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva/Ranbaxy launch Accupril generic

Executive Summary

Teva/Ranbaxy launch first generic version of Pfizer's Accupril (quinapril) Dec. 15 following FDA approval of Ranbaxy's ANDA. The generic is being manufactured by Ranbaxy, with Teva handling distribution and marketing pursuant to an exclusive supply agreement between the companies. Teva relinquished its 180-day exclusivity, allowing FDA to approve Ranbaxy's ANDA; five other companies hold tentative ANDA approval. Court rulings finding Teva's ANDA infringed a valid Pfizer patent prevented Teva from bringing its own generic to market (1"The Pink Sheet" July 5, 2004, p. 11)...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

PS045144

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel